VIDEO: Novel drug misses mark for MI prevention, but shows promise

WASHINGTON – In the large STABILITY trial, darapladib did not significantly reduce the primary endpoint of cardiovascular death, MI, or stroke in patients with stable coronary disease.

The novel...